AML is a phenotypically and genetically heterogeneous disease. Advances in molecular genetics and epigenetics led the World Health Organization to propose a novel classification based on cytogenetics, morphology and molecular genetics. 1 These new markers led to a better understanding of the leukemogenesis mechanism of AML, and provided insight into prognosis and potential targets for therapy. Furthermore, cytogenetically normal (CN)-AML has been identified as a heterogeneous disease with various mutations. The two most common genetic abnormalities in AML are frameshift mutations in nucleophosmin-1 (NPM1) and internal tandem duplications (ITDs) in feline mcdonough sarcoma (FMS)-related tyrosine kinase 3 (FLT3). 2 Patients with NPM1 mutations (NPM1-m) account for 45-60% of CN-AML with concomitant FLT3 mutation in 30% of patients. NPM1-m has a favorable prognosis in CN-AML when it is not associated with FLT3-ITD, whereas the opposite is true for patients with FLT3-ITD. 3 FLT3-ITD mutations are found in 20-30% of patients with AML and are more common in CN-AML. 2, 4 Another class of FLT3 mutations is point mutations in the tyrosine kinase domain (TKD), the most common being a point mutation in aspartic acid residue at position 835 (D835) that leads to a permanently open configuration and leads to constitutive signaling. FLT3-TKD mutation accounts for 5-10% of (CN)-AML, however, it has controversial prognostic significance. 5 Even though FLT3-ITD-positive patients have a similar CR rate, they usually present with a higher leukocyte count, and usually have shorter disease-free survival and overall survival, mainly due to frequent and early relapses. However, the recent use of sorafenib and other FLT3 inhibitors, and allogeneic stem cell transplantation (allo-SCT) has significantly improved outcome of FLT3-positive AML. 6, 7 Even though NPM1 and FLT3 mutations have been extensively studied independently, there have not been many studies investigating either the prognosis, or the dynamics of molecular response of NPM1-m and FLT3 together. 4, 8 The purpose of this retrospective study was to assess the dynamics of molecular response to treatment in adult AML patients with concomitant FLT3 and NPM1-m at diagnosis planned for allo-SCT, from 2011 January to 2016 December, at the American University of Beirut Medical Center (AUBMC). The study was approved by the institutional review board of AUBMC. We identified twelve consecutive patients (six females and six males) newly diagnosed (n = 11) or relapsed (n = 1) AML, who were selected according to the double-positive NPM1-m and FLT3 status at diagnosis of AML. All the patients and transplant characteristics are reported in Table 1 .
Patients received induction and consolidation chemotherapy using the combination of idarubicine and cytarabine given as follows: Idarubicine 12 mg/m 2 IV infusion over 1 h daily for 3 days (days 1-3) during the induction phase and for 2 days in consolidation; cytarabine 1.5 g/m 2 continuous infusion over 24 h daily on days 1-4 (age o 60 years) or days 1-3 (age ⩾ 60 years) during induction phase and at 0.75 g/m 2 for 3 days in consolidation. Abbreviations: ATG = anti-thymoglobulin; CR1 = first complete remission; CR2 = second complete remission; FB3 = fludarabine (5 days)+IV busulfan (3 days); FB4 = fludarabine (5 days)+IV busulfan (4 days); GvHD = graft versus host disease; Ida-AraC = idarubicin+cytarabine; TBF = thiotepa (2 days)+IV busulfan (3 days)+fludarabine (4 days).
Median age was 45 years (range 30-65 years). All patients had de novo AML. All patients had NPM1-m and positive FLT3 (10 had FLT3-ITD, 2 had FLT3-D835V). Ten patients had a normal diploid karyotype and two patients had abnormal karyotype. Ten patients achieved CR after one course of induction chemotherapy while two patients required double induction to achieve CR. All patients received at least one course of consolidation. All patients were planned for allo-SCT; however, two of them did not reach this point because of early death. Ten patients proceeded to allo-SCT with peripheral blood as stem cell source; seven patients from a matched-related donor and three from a haploidentical donor.
The median number of CD34 + infused stem cells was 6.58 × 10 6 /kg (range 4.4-10.1). GvHD prophylaxis consisted of cyclosporine A either alone (n = 7) or in combination with mycophenolate mofetil (n = 3). In addition, patients with a haploidentical donor also received two additional doses of cyclophosphamide post transplant.
The 10 transplanted patients received post-transplant sorafenib maintenance therapy. Most patients received an initial dose of 400 mg twice daily, and then adjusted to the best-tolerated dose according to side effects. Treatment was continued until disease progression. When side effects occurred, dose reduction and/or drug withdrawal were made as per treating physician decision. Sorafenib was started on median day 55 (range 29-137); four patients developed a transient rash after initiation of sorafenib. Of those, three patients discontinued sorafenib transiently due to exacerbation of the skin rash (skin biopsy was negative for acute GvHD) and one due to grade III hematologic toxicity. At the last follow-up, all patients are maintained on sorafenib, four of them are on reduced dose of sorafenib 200 mg (bis in die) twice daily (BID). All molecular studies were performed using bone marrow samples at diagnosis, on day 28 post induction, on day 21 after each consolidation, within two weeks before transplant and at days 30, 60 and 100 after allo-SCT and every 3 months afterwards. FLT3 mutation was tested on DNA using a qualitative method with a sensitivity of 0.01%. NPM1 mutation was tested on cDNA using a qualitative or a quantitative RT-PCR with a sensitivity of 0.01% and 0.008 normalized copy number (NCN), respectively. 10 The NPM1 correlated well before and after the transplant for all patients in consideration. The assay is quantitative and shows the NCN of NPM1 relative to an internal housekeeping gene. The FLT3 assay is qualitative in nature with an adequate sensitivity for follow-up; however, it does not provide an allelic burden.
After induction, FLT3 became negative in all tested patients (n = 12). It remained negative in 11 patients after consolidation, whereas a molecular relapse was noted in one patient who developed a hematological relapse and died. Another patient died after the third consolidation, in CR, due to septic shock. No molecular positivity for FLT3 was noted later on, whether after second consolidation or post transplant. FLT3 negativity was achieved before starting sorafenib maintenance therapy in all transplanted patients (Figure 1) .
Conversely, NPM1 mutation became negative in 2 out of 12 tested patients after induction, in 1 additional patient after first consolidation and in 7 additional patients after allo-SCT (4 before and 3 after sorafenib post SCT). NPM1 minimal residual disease (MRD) positive value increased in three out of four patients with quantitative assessment at diagnosis and post induction (Figure 1 ).
Three out of 10 patients (33%) developed a grade I acute GvHD before sorafenib introduction, successfully treated with topical steroids. Six patients were out of immunosuppressive treatment at the time of sorafenib introduction. After a median follow-up of 12.5 months (range 9-45 months) from transplant and 14 months (range 6-47) from diagnosis, 9 out of 10 transplanted patients remain alive, on sorafenib maintenance and disease free with MRD negative for both FLT3 and NPM1. One patient died because of severe refractory liver chronic GvHD, seven months post allo-SCT.
During the last decade, a number of prognostic cytogenetic and molecular markers have been identified in AML. 2 In this study, we have evaluated the dynamics of molecular response and the predictive value on the outcome of 12 patients with both NPM1-and FLT3-positive AML at diagnosis and afterwards undergoing allo-SCT followed by sorafenib as maintenance treatment. NPM1-m and FLT3 mutations are the most frequent predictive molecular markers in patients with AML 11, 12 However, again most of the data on molecular response were established separately for NPM1 or FLT3 mutation. 11, 13 There have not been many studies investigating the prognosis and the dynamics of molecular response of NPM1-m and FLT3 together.
Recently, a new study by the Acute Leukemia French Association Group assessed the prognostic impact of postinduction NPM1-m MRD in 152 young adult patients (age 18-60 years) with AML, and addressed the question of whether NPM1-m MRD may be used as a predictive factor of allo-SCT benefit. In these patients with non-favorable AML according to European Leukemia Net, disease free survival and overall survival were significantly improved by allo-SCT in those with a o 4-log reduction in peripheral blood (PB)-MRD. This benefit was not observed in those with a 44-log reduction in PB-MRD, with a significant interaction between allo-SCT effect and PB-MRD response.
14 This study supports the strong prognostic significance of early NPM1-m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1-m PB-MRD may be used as a predictive factor for allo-SCT indication. But only 59 patients had both NPM1 and FLT3-ITD positive, and they did not follow the dynamics of these concomitant molecular markers in the peri allo-SCT setting. 14, 15 Limitations of our study include its retrospective nature, a possible center effect and the small number of patients. Our findings indicate that FLT3 become negative early after induction while NPM1-m negativity lags behind and may become negative after sorafenib. This makes NPM1-m a potential candidate for MRD evaluation post allo-SCT. However, these results should be confirmed in larger prospective studies.
